5-HT2C Agonists for Weight Management and Smoking Cessation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatments are ineffective due to lack of efficacy or unacceptable side effects, and there is a need for safe and effective therapies for weight management, particularly in conjunction with smoking cessation, where weight gain is a significant barrier.
Innovation Solution
Development of 5-HT2C receptor agonists, such as those listed in Table A, which are administered to individuals to decrease food intake, induce satiety, and manage weight, while also aiding in smoking cessation and preventing associated weight gain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current obesity treatments are used, then weight loss may be achieved, but unacceptable side effects occur
Solution Approach 1:
The patent applies parameter changes by developing novel 5-HT2C receptor agonist compounds with optimized molecular structures (Formula 1 and analogs) that achieve effective weight loss while reducing harmful side effects. The chemical parameters including substitution patterns, stereochemistry, and molecular weight are systematically modified to improve the therapeutic index.
Solution Approach 2:
The patent uses 5-HT2C receptor agonists as intermediary substances that mediate between the nervous system and metabolic processes. These compounds act through the 5-HT2C receptor pathway to regulate appetite and energy expenditure, providing a mechanistic bridge that achieves weight loss through physiological regulation rather than direct metabolic interference, thereby reducing side effects.
2Ease of operation
If diet and lifestyle advice is given, then obesity management is recommended, but patient compliance is difficult to maintain
Solution Approach 1:
The patent enables self-service by providing patients with an autonomous pharmacological solution that works independently of behavioral modification. The 5-HT2C agonist compounds automatically regulate appetite and satiety signals, allowing patients to maintain weight loss without requiring constant self-monitoring or willpower, thus improving compliance while ensuring reliable treatment effectiveness.
3Object-affected harmful factors
If smoking cessation is pursued, then health benefits are achieved, but weight gain occurs as a barrier
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating or concurrently treating smoking cessation patients with 5-HT2C agonist compounds to prevent the anticipated weight gain. This proactive approach counteracts the compensatory eating behavior that typically follows smoking cessation, allowing patients to achieve both smoking cessation and weight management goals simultaneously.
Data Source
AI summary
Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided in some embodiments are compositions comprising a compound herein, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a compound herein, optionally in combination with a supplemental agent.